AHIP Outlines Priorities For Post-PHE Telehealth Policy Changes

Lawmakers at the state and federal levels can continue the benefits of telehealth access by making permanent pandemic-era flexibilities, embracing audio-only visits, allowing telehealth across state lines, not requiring payment parity between virtual and in-person care, and using digital health to improve equity and mental health access past the end of the COVID-19 public health emergency, the health insurance lobby says in a new white paper. But the AHIP white paper warns that to cement such reforms, policy makers need...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 




Medicare, Medicaid Spent $18B On Accelerated Approval Drugs With Late Studies

Medicare and Medicaid spent more than $18 billion over four years on accelerated approval drugs with late post-market trials that are meant to confirm the drugs work, according to the HHS Inspector General, which released its findings the same day the Senate passed FDA user fee legislation from which accelerated approval reforms were stripped. FDA accelerated approvals allow sales of promising treatments for serious illnesses before clinical trials confirm they work. That process is being scrutinized after FDA approved the...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 
Topics: 








CMS: MA Premiums Set To Drop 8% in 2023, Plan Finder Won’t Show $35 Insulin

CMS on Thursday (Sept. 29) announced Medicare Advantage premiums are set to drop to an average of $18 a month for 2023, down about 8% from 2022, and the agency estimates 31.8 million people will sign up for an MA plan for 2023 as Medicare open enrollment starts Oct. 15. But CMS slides on Medicare open enrollment say initial plan information -- and the Medicare Plan Finder -- for MA and Part D doesn’t consider the Inflation Reduction Act’s policies...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Email Subject Line: 
Latest MA News
Author: 
Secondary Author(s): 

FDA Approves ALS Drug; Has Vowed To Pull Drug If New Data Raise Flags

FDA on Thursday (Sept. 29) approved Amylyx Pharmaceuticals’ high-profile amyotrophic lateral sclerosis drug Relyvrio, which FDA and the company say could potentially meet an unmet need in ALS treatment, even though questions have been raised about the drug’s efficacy. FDA and Amylyx have committed to pull Relyvrio from the market if future data show it to be ineffective. “To be clear, if PHOENIX is not successful, we will do what is right for patients, which includes voluntarily removing from it...
Article Type: 
Site Name: 
InsideHealthPolicy.com
Author: 

Pages

Log in to access this content.

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.